J&J touts success of nipocalimab in two rare disease trials
J&J’s nipocalimab met primary endpoints in Phase III and II trials for myasthenia gravis and Sjogren’s disease, respectively.
J&J’s nipocalimab met primary endpoints in Phase III and II trials for myasthenia gravis and Sjogren’s disease, respectively.
What's Your Reaction?
